The 36-month beta value for CAPR is at 4.09. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAPR is 39.96M, and currently, shorts hold a 13.99% of that float. The average trading volume for CAPR on January 03, 2025 was 2.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CAPR) stock’s latest price update
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) has jumped by 8.41 compared to previous close of 13.80. Despite this, the company has seen a gain of 6.78% in its stock price over the last five trading days. globenewswire.com reported 2025-01-02 that -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. “The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD.
CAPR’s Market Performance
Capricor Therapeutics Inc (CAPR) has experienced a 6.78% rise in stock performance for the past week, with a -23.83% drop in the past month, and a -9.44% drop in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 10.21% for CAPR. The simple moving average for the last 20 days is 7.51% for CAPR’s stock, with a simple moving average of 61.07% for the last 200 days.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Piper Sandler repeating the rating for CAPR by listing it as a “Overweight.” The predicted price for CAPR in the upcoming period, according to Piper Sandler is $35 based on the research report published on October 21, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $14. The rating they have provided for CAPR stocks is “Outperform” according to the report published on May 17th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CAPR, setting the target price at $8 in the report published on January 05th of the previous year.
CAPR Trading at -12.71% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.07% of loss for the given period.
Volatility was left at 10.21%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -9.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.27% lower at present.
During the last 5 trading sessions, CAPR rose by +6.78%, which changed the moving average for the period of 200-days by +121.30% in comparison to the 20-day moving average, which settled at $13.91. In addition, Capricor Therapeutics Inc saw 8.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.55 for the present operating margin
- 0.96 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.47. The total capital return value is set at 0.0. Equity return is now at value -102.63, with -52.44 for asset returns.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 1.92. When we switch over and look at the enterprise to sales, we see a ratio of 26.41. The receivables turnover for the company is 56.7for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.19.
Conclusion
In conclusion, Capricor Therapeutics Inc (CAPR) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
